Tromsø, Norway, 2. April 2019 - Biotec Pharmacon (OSE: Biotec) announced today
that its subsidiary, ArcticZymes, has been granted  Euro 254k as part of a
collaborative project on the development of novel enzymes for synthetic
biology.
The project proposal was developed in collaboration with the University of
Tromsø and Danish company, Legomics, has been positively evaluated by the
Eurostars programme. ArcticZymes is to participate in developing novel DNA
ligases, enabling novel chemistry for synthetizing DNA and genes to be further
developed by Legomics.

Working alongside the University of Tromsø, ArcticZymes have used Arctic marine
bioprospecting and engineering to establish a substantial base for the
development of enzymes with novel unique properties.

ArcticZymes Managing Director Jethro Holter said:

"This project supports ArcticZymes ambitions towards building a broader
synergistic product portfolio, with wide applicability across all three
molecular biology market segments it serves - research, IVD and therapeutics. We
are also excited to partner with Legomics and the University of Tromsø in
enabling a novel gene synthesis technology."

Christian Jørgensen, CEO, added:

"The project will further strengthen our long-term collaboration with the
University of Tromsø in the discovery of other classes of unique enzymes.
Furthermore, we are looking forward to establishing a closer relationship with
Legomics and developing enzyme technology for use in gene synthesis technology
and various other applications."

-ENDS-

For more information, please contact:

Biotec Pharmacon
Christian Jørgensen, CEO                                           Tel: +47 47
79 24 57
Dr Jethro Holter, MD ArcticZymes                               Tel: + 47 46 85
91 46

    Email: contact@arcticzymes.com

Instinctif Partners
Melanie Toyne-Sewell / Dr Christelle Kerouedan /       Tel: +44 207 457 2020
Deborah Bell
Biotecpharmacon@instinctif.com

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsoe to offer niche and high-tech products in
several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon's unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About ArticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in
molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes. Some of its enzymes' unique features include heat
lability and activity in challenging environments as well as customised,
engineered novel features which can be integrated to power the technologies of
commercial partners.

All ArcticZymes products are ISO certified.

For more information, please visit: www.arcticzymes.com

About University of Tromsø

UiT The Arctic University of Norway (https://en.uit.no/startsida) is the world's
northernmost University which is reflected in the strong innovation focus of its
research activities, often drawing on this unique geographical location. The
department of Chemistry has a strong profile in cold-active enzyme discovery and
engineering for biotechnological purposes. This is facilitated by superb access
to sampling locations in Arctic regions, in-house competence regarding biomining
of (meta)genomic data and cutting-edge structural biology infrastructure through
the national NorCryst platform. The translation of fundamental scientific
findings to commercial solutions is enabled by collaboration with industrial
partners and participation in innovation-focused projects at national and
international levels.

About Legomics

Legomics is a Danish company and spin-off of Genomic Expression. Legomics
technology enables the development of a desktop gene writer using enzymes.

Other chemistries for DNA synthesis are based on harsh organic chemicals and
bulky pipetting robots for the assembly of all the fragments. It is a tedious
and time-consuming process because smaller custom-made pieces of DNA have to be
assembled by hand or with a pipetting robot giving a lead time of 2-4 weeks to
get a new piece of DNA comprising one or more genes. By an enzymatic driven
process, Legomics aims to develop the technology for a desktop gene writer that
would increase speed and lower the cost of DNA- and gene synthesis,
democratizing the process and fueling new innovations.

About Eurostars

Eurostars supports international innovative projects led by research and
development- performing small- and medium-sized
enterprises (https://www.eurostars-eureka.eu/eurostars-faq) (R&D-performing
SMEs). With its bottom-up approach, Eurostars supports the development of
rapidly marketable innovative products, processes and services that help improve
the daily lives of people around the world. Eurostars has been carefully
developed to meet the specific needs of SMEs. It is an ideal first step in
international cooperation, enabling small businesses to combine and share
expertise and benefit from working beyond national borders.

Eurostars is a joint programme between EUREKA and the European Commission, co
-funded from the national budgets of 36 Eurostars Participating States and
Partner Countries (https://www.eurostars-eureka.eu/eurostars-faq) and by the
European Union through Horizon 2020. In the 2014-2020 period it has a total
public budget of  Euro 1.14 billion.

For more information, please visit www.eurostars-eureka.eu